Prevention in neglected subpopulations: Prevention of mother-to-child transmission of HIV infection

Clinical Infectious Diseases

Volumn 50, Issue SUPPL. 3, 2010, Pages

  Mofenson, Lynne M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

BREAST FEEDING; BREAST MILK; CESAREAN SECTION; CHILDBIRTH; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE TRANSMISSION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TEST; INFANT FEEDING; INFECTION PREVENTION; MATERNAL WELFARE; PATIENT COUNSELING; PREGNANCY; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TERATOGENICITY; TREATMENT DURATION; UNITED STATES; VERTICAL TRANSMISSION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; BREAST FEEDING; CESAREAN SECTION; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 77951872136     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651484     Document Type: Review

References (108)

1. World Health Organization/UNAIDS. AIDS Epidemic Update: December 2009. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS and World Health Organization, 2009. http://data.unaids.org/pub/Report/2009/2009-epidemic- update-en.pdf. Accessed 17 December 2009.
2. DeCock KM, Fowler MG, Mercier E, et al. Prevention of mother-tochild HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175-1182. (Pubitemid 30126606)
3. Townsend CL, Cortina-Boria M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981.
4. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings; towards universal access-recommendations for a public health approach 2006. Geneva, Switzerland: World Health Organization, 2006.
5. World Health Organization. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants-November 2009. Geneva, Switzerland: World Health Organization, 2009. http://www.who.int/hiv/ pub/mtct/rapid-advice-mtct.pdf. Accessed 17 December 2009.
6. Chilongozi D, Wang L, Brown L, et al. Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis J 2008; 27:808-814.
7. World Health Organization. Strategic approaches to the prevention of HIV infection in infants: report of a WHO meeting, Morges, Switzerland, 20-22 March 2002. WHO, 2003. http://www.who.int/hiv/mtct/StrategicApproaches.pdf. Accessed 17 December 2009.
8. 8. Morrison CS, Wang J, van der Pol B, et al. Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS 2007;21:1027-1034. (Pubitemid 46684334)
9. Gray R, Li X, Kigozi G, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 2005; 366: 1182-1188.
10. Moodley D, Esterhuizen TM, Pather T, Chetty V, Ngaleka L. High HIV incidence during pregnancy: compelling reason for repeat HIV testing. AIDS 2009;23:1255-1259.
11. Patterson KB, Leone PA, Fiscus SA, et al. Frequent detection of acute HIV infection in pregnant women. AIDS 2007;21:2303-2308. (Pubitemid 350287456)
12. Lu L, Legwaila K, Motswere C, et al. HIV incidence in pregnancy and the first post-partum year and implications for PMTCT programs, Francistown, Botswana, 2008. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Abstract 91.
13. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health care sector- progress report 2009. Geneva, Switzerland: World Health Organization, 2009. http://www.who.int/hiv/pub/tuapr- 2009-en.pdf. Accessed 17 December 2009.
14. Reynolds HW, Janowitz B, Wilcher R, Cates W. Contraception to prevent HIV-positive births: current contribution and potential costsavings in PEPFAR countries. Sex Transm Infect 2008; 84(Suppl 2): 49-53.
15. Rochat TJ, Richter LM, Doll HA, et al. Depression among pregnant rural South African women undergoing HIV testing. JAMA 2006; 295:1376-1378.
16. Homsy J, Bunnell R, Moore D, et al. Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study. PLoS ONE 2009; 4:e4149.
17. Desgrees-du-Lou A, Msellati P, Viho I, et al. Contraceptive use, protected sexual intercourse, and incidence of pregnancies among African HIV-infected women, Int J STD AIDS 2002; 13:462-1168
18. Reynolds HW, Steiner MJ, Cates W Jr. Contraception's proved potential to fight HIV. Sex Transm Infect 2005; 81:184-185.
19. Pai NP, Tulsky JP, Cohan D, et al. Rapid point of care HIV testing in pregnant women: a systematic review and meta-analysis. Trop Med Int Health 2007; 12:162-173. (Pubitemid 46244172)
20. Creek TL, Ntumy R, Seipone K, et al. Successful introduction of routine opt-out HIV testing in antenatal care in Botswana. JAIDS 2007; 45:102-107. (Pubitemid 46684449)
21. Chandisarewa W, Stranix-Chibanda L, Chirapa E, et al. Routine offer of antenatal HIV testing ("opt-out" approach) to prevent mother to child transmission of HIV in urban Zimbabwe. Bull WHO 2007; 85: 843-850. (Pubitemid 350086456)
22. Medley A, Garcia-Moreno C, McGill S, Maman S. Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes. Bull WHO 2004; 82:299-307. (Pubitemid 38568468)
23. Kakimoto K, Kanal K, Mukoyama Y, et al. Influence of the involve-ment of partners in the mother class with voluntary confidential counseling and testing acceptance for prevention of mother to child transmission of HIV programme (PMTCT programme) in Cambodia. AIDS Care 2007; 19:381-384. (Pubitemid 46572926)
24. Msuya SE, Mbizvo EM, Hussain A, et al. Low male partner participation in antenatal HIV counseling and testing in northern Tanzania: implications for preventive programs. AIDS Care 2008; 20:700-709. (Pubitemid 351913396)
25. Kizito D, Woodburn PW, Kesande B, et al. Uptake of HIV and syphilis testing of pregnant women and their male partners in a programme for prevention of mother-to-child HIV transmission in Uganda. Trop Med Int Health 2008; 13:680-682. (Pubitemid 351561614)
26. Sarker M, Sanou A, Snow R, et al. Determinants of HIV counseling and testing participation in a prevention of mother-to-child transmission programme in rural Burkina Faso. Trop Med Int Health 2007; 12:1475-1483. (Pubitemid 350212715)
27. Homsy J, King R, Malamba SS, et al. The need for partner consent is a main reason for opting out of routine HIV testing for prevention of mother-to-child transmission in a rural Ugandan hospital. JAIDS 2007; 44:366-369. (Pubitemid 46328360)
28. Farquhar C, Kiarie JN, Richardson BA, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. JAIDS 2004; 37:1620-1626. (Pubitemid 39658204)
29. Tonwe-Gold B, Ekouevi DK, Bosse CA, et al. Implementing familyfocused HIV care and treatment: The first 2 years' experience of the mother-to-child transmission-plus program in Abidjan, Côte d'Ivoire. Trop Med Int Health 2009; 14:204-212.
30. UNICEF. Children and HIV and AIDS, http://www.unicef.org/aids/index.php. Accessed 26 November 2009.
31. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: toward universal access, recommendations for a public health approach 2006 revision. Geneva, Switzerland: World Health Organization, 2006.
32. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009:1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 17 December 2009.
33. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents- November 2009. Geneva, Switzerland: World Health Organization, 2009.http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf. Accessed 17 December 2009.
34. Severe P, Pape J, Fitzgerald DW, et al. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T cell count of 200-350 cells/mL (CIPRAHT001). In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). 2009. Abstract H-1230.
35. 35. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228. (Pubitemid 38916040)
36. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: The Mashi Study. JAMA 2006; 296: 794-805.
37. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-tochild transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: The Mitra Study. JAIDS 2008; 48:315-323.
38. Vyankandondera J, Luchters S, Hassink E, et al. Simba-Stopping Infection from Mother to Child via Breastfeeding in Africa. In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis (Paris, France). 2003. Abstract LB07.
39. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extendeddose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300-313.
40. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119-129.
41. Chasela C, Hudgens M, Jaimeson D, et al. Both maternal HAART and daily infant nevirapine (NVP) are effective in reducing HIV-1 transmission during breastfeeding in a randomized trial in Malawi: 28 week results of the Breastfeeding, Antiretroviral and Nutrition (BAN) Study. In: Program ans abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (Capetown, South Africa). 2009. Abstract WeLB C103.
42. de Vincenzi I, Kesho Bora Study Group. Triple-antiretroviral prophylaxis during pregnancy and breastfeeding compared to short-ARV prophylaxis to prevent mother-to-child transmission of HIV-1: The Kesho Bora randomized controlled clinical trial in five sites in Burkina Faso, Kenya and South Africa. In: Program and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (Capetown, South Africa). 2009. Abstract LBPE COl.
43. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 29 April 2009:1-90. http://aidsinfo.nih.gov/ContentFiles/ PerinatalGL.pdf. Accessed 17 December 2009.
44. 44. Phanuphak N, Apornpong T, Teeratakulpisam S, et al. Nevirapineassociated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med 2007; 8:357-366. (Pubitemid 47163267)
45. McKoy JM, Bennett CL, Scheetz MH, et al. Hepatotoxicity associated with long versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug Events and Reports (RADAR) Project. Drug Safety 2009; 32:147-158.
46. Desgrees-du-Lou A, Msellati P, Viho I, et al. Incidence of pregnancies among African HIV-infected women, Abidijan, 1995-2000. AIDS 2001; 15:2327-2330.
47. El-Sadr WM, Lundgren JD, Neaton JD, et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study GroupCD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
48. El-Sadr WM, Grund B, Neuhaus J, et al.; SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149:289-299.
49. 49. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019-1026. (Pubitemid 46684333)
50. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195-1201.
51. 51. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870. (Pubitemid 34603030)
52. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85:82-87.
53. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS 2008; 22:1815-1820.
54. Shapiro R, Hughes M, Ogwu A, et al. The Mma Bana Study: randomized trial comparing highly active antiretroviral therapy regimens for virologic efficacy and the prevention of mother-to-child HIV transmission among breastfeeding women in Botswana. In: Program and abstracts of the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (Capetown, South Africa). 2009. Abstract WeLB B010.
55. 55. Barret, B, Tardieu, M, Rustin, P, et al. Persistent mitochondrial dys function in HIV-1-exposed but uninfected infants: Clinical screening in a large prospective cohort. AIDS 2003; 17:1769-1785. (Pubitemid 37000095)
56. Thome C, Newell ML. Safety of agents used to prevent mother-tochild transmission of HIV: is there any cause for concern? Drug Safety 2007; 30:203-213.
57. Ciarnello AL, Seage GR 3rd, Freedberg KA, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS 2008; 22: 2359-2369.
58. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369: 1107-1116.
59. Bland RM, Little KE, Coovadia HM, et al. Intervention to promote exclusive breast-feeding for the first 6 months of life in a high HIV prevalence area. AIDS 2008; 22:883-891.
60. Kuhn L, Reitz C, Abrams EJ. Breastfeeding and AIDS in the developing world. Curr Opin Pediatr 2009; 21:83-93.
61. 61. Marazzi C, Germano P, Liotta G, et al. Implementing anti-retroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settings. Eur J Pediatr 2007; 166: 1305-1307. (Pubitemid 350029474)
62. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21(Suppl 4):S65-S71.
63. Thomas T, Masaba R, Ndivo R, et al. Prevention of mother-to-child transmission of HIV-1 among breastfeeding mothers using HAART: The Kisumu Breastfeeding Study, Kisumu, Kenya, 2003-2007. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Boston). 2008. Abstract 45aLB.
64. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-tochild transmission of HIV-1 through breastfeeding by treating mothers prophylactically with triple antiretroviral therapy in Dar es Salaam, Tanzania - the Mitra PLUS study. JAIDS 2009; 52(3):406-416.
65. Peltier CA, Ndayisaba GF, Lepage P, et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother to child infection in Rwanda. AIDS 2009; 23:2415-2423.
66. 66. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130-141. (Pubitemid 351962036)
67. Kafulafula G, Hoover D, Taha TE et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53:6-13.
68. Thomas T, Masaba R, van Eijk A, et al. Rates of diarrhea associated with early weaning among infants in Kisumu, Kenya. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Boston). 2008. Abstract 774.
69. Mach O, Lu L, Creek T, et al. Population-based study of a widespread outbreak of diarrhea associated with increased mortality and malnutrition in Botswana, January-March 2006. Am J Trop Med Hyg 2009; 80:812-818.
70. Homsy J, Moore D, Barasa A, et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2010; 53:28-35.
71. World Health Organization. Rapid advice: infant feeding in the context of HIV-November 2009. Geneva, Switzerland: World Health Organization, 2009. http://www.who.int/hiv/pub/paediatric/rapid-advice-infant.pdf. Accessed 17 December 2009.
72. 72. Israel-Ballard K, Donovan R, Chantry C, et al. Flash-heat inactivation of HIV-1 in human milk: a potential method to reduce postnatal transmission in developing countries. JAIDS 2007; 45:318-323. (Pubitemid 47012379)
73. 73. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dosenevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. JAIDS 2005; 38:283-288. (Pubitemid 40333492)
74. 74. Arrive E, Newell M-L, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis, Int J Epidemiol 2007; 36:1009-1021. (Pubitemid 350018545)
75. 75. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192: 30-36. (Pubitemid 40863854)
76. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C and D. JAIDS 2006; 42: 610-613.
77. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother to child HIV transmission. AIDS 2006; 20:995-1002.
78. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine vs placebo as part of an antiretroviral strategy to prevent mother to child HIV transmission in Botswana. AIDS 2006; 20:1281-1288.
79. 79. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240. (Pubitemid 38922817)
80. Flys TS, McConnell MS, Matovu F, et al. Nevirapine resistance in women and infants after first vs repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis 2008; 198: 465-1169
81. 81. Van Zyl GU, Claassen M, Engelbrecht S, et al. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. J Med Virol 2008; 80:942-946. (Pubitemid 351657002)
82. 82. Cunningham CK, Chaix M-L, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis 2002; 186: 181-188. (Pubitemid 34765505)
83. Eshelman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-2168.
84. Church JD, Omer SB, Guay LA, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV-infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008; 198:1075-1082.
85. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-1957.
86. 86. Kurle SN, Gangakhedkar RR, Sen S, et al. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India. AIDS Res Hum Retroviruses 2007; 23:682-685. (Pubitemid 46867465)
87. 87. Martinson NA, Morris L, Gray G, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. JAIDS 2007; 44:148-153. (Pubitemid 46292216)
88. Nelson JAE, Loftis AM, Kamwendo D, et al. Nevirapine resistance in human immunodeficiency virus type 1-positive infants determined using dried blood spots stored for up to six years at room temperature. J Clin Microbiol 2009; 47:1209-1211.
89. Mclntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6:e1000172.
90. 90. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-1705. (Pubitemid 350100773)
91. Van Dyke R, Jourdain G, Shapiro D, et al. A phase II study of the incidence of nevirapine resistance mutations in HIV-infected Thai women receiving a single intrapartum dose of NVP followed by a postpartum tail of ZDV/ddI or ZDV/ddI/LPV/r: IMPAACT P1032. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Abstract 95aLB.
92. Farr S, Nelson J, Ng'ombe T, et al. Addition of 7 days of zidovudine + lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance at 2 and 6 weeks post-partum in HIV-infected mothers: Lilongwe, Malawi. In: Program ans abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Abstract 958b.
93. Lallemant M, Ngo-Giang-Huong N, Jourdain G, et al.; PHPT-4 Study Team. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum singledose nevirapine. Clin Infect Dis 2010; 50:898-908.
94. The TEmAA ANRS 12109 Study Group; Arrivé E, Chaix ML, Nerrienet E, et al. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 2009; 23:825-833.
95. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-I: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Côte d'Ivoire. J Infect Dis 2006; 193:482-1187 (Pubitemid 43202738)
96. Eshleman SH, Hoover DR, Hudelson SE, et al. Development of nevirapine resistance in infants is reduced by use of infant-only singledose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis 2006; 193:479-1181
97. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE 2009; 4:e4096.
98. 98. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195:711-715. (Pubitemid 46273046)
99. Wind-Rotolo M, Durand C, Cranmer L, et al. Identification of nevirapine resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis 2009; 199:1301-1309.
100. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitorbased therapy. Clin Infect Dis 2009; 48:462-1172
101. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
102. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007; 21:957-964. (Pubitemid 46684327)
103. Lockman S and A5208/OCTANE Study Team. Lopinavir/ritonavir + tenofovir/emtricitabine is superior to nevirapine + tenofovir/emtricitabine for women with prior exposure to single-dose nevirapine: A5208 ("Octane"). In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Abstract 94LB.
104. Zeh C, Weidle P, Nafisa L, et al. Emergence of HIV-1 drug resistance among breastfeeding infants born to HIV-infected mothers taking antiretrovirals for prevention of mother-to-child transmission of HIV: The Kisumu Breastfeeding Study, Kenya. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008. Abstract 84LB.
105. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53: 1170-1176.
106. Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005; 19:1912-1915. (Pubitemid 41546612)
107. Nakakeeto ON, Kumaranayake L. The global strategy to eliminate HIV infection in infants and young children: a seven country assessment of costs and feasibility. AIDS 2009; 23:987-995.
108. Stringer EM, Chi H, Chintu N, et al. Monitoring effectiveness of programmes to prevent mother to child HIV transmission in lower income countries. Bull WHO 2008; 86:57-62.